The presence of acute pain can be the worst negative impressions of a person. Therefore, it is necessary to ensure the control of acute pain for comfort and prevention of the formation of chronic pain syndrome intraoperatively. The development of a multimodal approach to the control of acute pain allows for shorter results. The more we use antinociceptive receptors for pain control, the more comfortable our patient feels. Alpha-2-adrenergic agonists (clonidine, dexmedetomidine) became a key part of the anesthesiologist’s recruitment in the perioperative period. The very selective infusion of dexmedetomidine on alpha-2a central and peripheral receptors and alpha-2c receptors allowed the drug to be more widely absorbed during procedural sedation. The need for more drugs for procedural sedation may be taken to the maximum possible comfort for the patient, the happy doctor and the anesthesiological team, the change in drug administration and the most likely awakening. To balance and satisfy the needs of the consumer to help the most practical way to achieve the goal of combinations of drugs and analysis of useful and negative effects. Special notice. There are presented two cases with typical development but different in terms of surgical applications of clinical manifestations of the described effects, associated with the intake of Kvanadex (dexmedetomidine hydrochloride) during procedural sedation in outpatient dentistry. Conclusions. The administration of dexmedetomidine (Kvanadex) intraoperatively together with propofol during procedural sedation in outpatient dentistry allows to control the pain in the perioperative period with vicarious treatment of basic traditional drugs (acetaminophen, NSAIDs) in non-healing doses, changing the dose of propofol during the procedure, reducing the vomit reflex, allowing for a comfortable follow-up of the doctor’s commands (surgeon, implantologist, orthopedist) and more rapid transfer of the patient to the awakening ward.
In the previous publication, we outlined the general principles of procedural sedation (PS), the depth of suppression of consciousness and spontaneous motor activity, the minimum quantity of patients' pre-procedural examinations and the aspects of informed consent obtaining. The principles of vital signs monitoring, patients' immobilisation, and the detection and treatment of adverse events have been described. A key aspect of the PS is the readiness to ensure patency of the airways and oxygenation at least one level deeper than the existing level of the PS. In this publication, attention is focused on the pharmacokinetics and pharmacodynamics of propofol and dexmedetomidine - the main drugs for elective PS and on the combination between them. In a future publication, we plan to characterize other key medications for PS, such as midazolam, ketamine, thiopental, and fentanyl. Propofol is a short-track anaesthesia drug, and it was the most widely distributed in the 21st century because after its use patients quickly and fully regain consciousness. At the same time, to achieve the necessary deep level of sedation and prevent unintended movements of the patient, it is often required to use high doses of propofol that can cause clinically significant suppression of the patency of the upper respiratory airways, depth of breathing, and hemodynamic. Therefore, in this publication, we promote the implementation of multimodal sedation and analgesia with the use of moderate doses of several drugs, which allows a significant reduction in the dose of propofol and thus increase the safety of PS. Dexmedetomidine has both sedative and analgesic properties with a minimal effect on the patency of the upper airways and the depth of breathing, thus is the best drug to combine with propofol in PS. In children, intranasal administration of dexmedetomidine and midazolam is an important alternative method of premedication, which provides a gentle entry into sedation and prevents the child's stress reactions to the placement of a venous catheter. Although the use of dexmedetomidine in children's practice is still "off-label" and outside the indications approved by the FDA in this publication we provide evidence to justify its safety and effectiveness of its usage in paediatrics PS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.